Critical signaling pathways in bone sarcoma: Candidates for therapeutic interventions

Current Oncology Reports

Volumn 11, Issue 6, 2009, Pages 446-453

  Geryk Hall, Mandy ^a   Hughes, Dennis P M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CHELERYTHRINE; CISPLATIN; DASATINIB; DEATH RECEPTOR; DEFOROLIMUS; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EZRIN; GEMCITABINE; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NERVE GROWTH FACTOR RECEPTOR; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SHC; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAPAMYCIN; SCH 717454; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TIPIFARNIB; UNCLASSIFIED DRUG; WNT PROTEIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BONE CANCER; BONE DEVELOPMENT; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL SHAPE; CELL SURFACE; CHONDROSARCOMA; CLINICAL TRIAL; DIMERIZATION; DOWN REGULATION; ENZYME ACTIVATION; EWING SARCOMA; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LIGAND BINDING; LUNG METASTASIS; NONHUMAN; OSTEOSARCOMA; PRENYLATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; RECEPTORS, CELL SURFACE; SARCOMA; SIGNAL TRANSDUCTION;

EID: 70350150140     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0061-z     Document Type: Review

References (50)

1. Kim SY, Toretsky JA, Scher D, Helman LJ: The role of IGF-1R in pediatric malignancies. Oncologist 2009, 14:83-91.
2. Britten CD: Targeting ErbB reAeptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 2004, 3:1335-1342.
3. Ren L, Hong SH, Cassavaugh J, et al.: The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009, 28:792-802.
4. Garcia JA, Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008, 7:1347-1354.
5. Shih I-M, Wang T-L: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007, 67:1879-1882.
6. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
7. Greil R, Anether G, Johrer K, Tinhofer I: Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: Pathways, targets, and therapeutic tools. J Leukoc Biol 2003, 74:311-330.
8. Pompetti F, Rizzo P, Simon RM, et al.: Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 1996, 63:37-50.
9. Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
10. Toguchida J, Yamaguchi T, Dayton SH, et al.: Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992, 326:1301-1308.
11. Yokoyama R, Schneider-Stock R, Radig K, et al.: Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract 1998, 194:615-621.
12. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ: Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994, 54:2803-2807.
13. Kolb EA, Gorlick R, Houghton PJ, et al.: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1190-1197.
14. Hughes DPM, Thomas DG, Giordano TJ, et al.: Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004, 64:2047-2053.
15. Wen YH, Koeppen H, Garcia R, et al.: Epidermal growth factor receptor in osteosarcoma: Expression and mutational analysis. Hum Pathol 2007, 38:1184-1191.
16. Messerschmitt PJ, Rettew AN, Brookover RE, et al.: Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008, 466:2168-2175.
17. Hingorani P, Zhang W, Gorlick R, Kolb EA: Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009, 15:3416-3422.
18. Reinholz GG, Getz B, Pederson L, et al.: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
19. Ory B, Blanchard F, Battaglia S, et al.: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007, 71:333-343.
20. Ferrari S, Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007, 19:341-346.
21. Yang R, Piperdi S, Gorlick R: Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 2008, 14: 6396-404.
22. Hall-Geryk M YY, Hughes DPM: Inhibiting farnesylation in osteosarcoma [abstract 3759]. Presented at the 99th Annual Meeting of the American Association of Cancer Research. San Diego, CA; April 12-16, 2008.
23. Woessmann W, Chen X, Borkhardt A: Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol. 2002, 50:397-404.
24. Ory B, Moriceau G, Redini F, Heymann D: MTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: Bi-functional compounds for the treatment of bone tumours. Curr Med Chem 2007, 14:1381-1387.
25. Wan X, Mendoza A, Khanna C, Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005, 65:2406-2411.
26. Gautreau A, Poullet P, Louvard D, Arpin M: Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. PNAS 1999, 96:7300-7305.
27. Wan X, Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 2007, 12:1007-1018.
28. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM: Critical role of Notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008, 14:2962-2969.
29. Engin F, Bertin T, Ma O, et al.: Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 2009, 18:1464-1470.
30. Tanaka M, Setoguchi T, Hirotsu M, et al.: Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 2009, 100:1957-1965.
31. Kikuchi A. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000, 268:243-248.
32. Hoang BH, Kubo T, Healey JH, et al.: Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004, 109:106-111.
33. Chen K, Fallen S, Abaan HO, et al.: Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 2008, 51:349-355.
34. Lee N, Smolarz AJ, Olson S, et al.: A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 2007, 97:1552-1559.
35. Koshkina NV, Khanna C, Mendoza A, et al.: Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007, 5:991-999.
36. Gordon N, Arndt CA, Hawkins DS, et al.: Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005, 27:611-615.
37. Gordon N, Koshkina NV, Jia S-F, et al.: Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007, 13:4503-4510.
38. Hou P, Ji M, Yang B, et al.: Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 2006, 106:1602-1609.
39. Lim S, Yang MH, Park JH, et al.: Inactivation of the RASSF1A in osteosarcoma. Oncol Rep 2003, 10:897-901.
40. Schaefer KL, Eisenacher M, Braun Y, et al.: Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008, 44:699-709.
41. Toretsky JA, Kalebic T, Blakesley V, et al.: The insulin-like growth factor-i receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822-308227.
42. Scotlandi K, Manara MC, Nicoletti G, et al.: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65:3868-3876.
43. Atzori F, Tabernero J, Cervantes A, et al.: A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors [abstract]. ASCO Meeting Abstracts 2008, 26:3519.
44. Kang H-G, Jenabi JM, Zhang J, et al.: E-cadherin cell-cell adhesion in Ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res 2007, 67:3094-3105.
45. Dalal S, Berry AM, Cullinane CJ, et al.: Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005, 11:2364-2378.
46. Reddy K, Zhou Z, Jia SF, et al.: Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer 2008, 123:831-837.
47. Zhou Z, Bolontrade MF, Reddy K, et al.: Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007, 13:4867-4873.
48. Uren A, Wolf V, Sun YF, et al.: Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer 2004, 43:243-249.
49. Guan H, Zhou Z, Gallick GE, et al.: Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 2008, 7:1807-1816.
50. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC: Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005, 6:599-607.